AcelRx Pharmaceuticals, Inc. (ACRX) insider have most recently took part in a trading activity. On Aug 24, 2017 Edwards Mark G, Director bought 5,000 shares having total worth of $15,100 at the price of $3.02 per share, following the transaction a total of 120,000 shares owned by Edwards Mark G.
The stock has experienced a total of 2 insider trades in the past three months. These trades include 1 sell activities and 1 buy trades. Furthermore, over the past 12 months , the stock was traded 4 times by insiders. In 3 of these trades, the insider was a seller while an employee of the company was the buyer in 1 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of AcelRx Pharmaceuticals, Inc. (ACRX) traded up 1.69% on Aug 23, 2017, hitting $3. 797,195 shares of the company’s stock traded hands. AcelRx Pharmaceuticals, Inc. has a 52 week low of $2.05 and a 52 week high of $3.9. The company’s market cap is $174 million.
AcelRx Pharmaceuticals, Inc. (ACRX) last announced its earnings results on Aug 1, 2017. The company reported -0.29 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.27 by $0.02. The company had revenue of $3 million for the quarter, compared to the consensus estimate of $2 million. During the same quarter in the previous year, the company posted -0.24 earnings per share. The company’s revenue for the quarter was down 41% on a year-over-year basis.
|earnings per share||-0.29||-0.34||-0.21||-0.25||-0.24||-0.25||-0.24||0.11||-0.20||-0.27|
Acelrx Pharmaceuticals Inc. is a specialty pharmaceutical company involved in the development and commercialization of therapies for the treatment of acute and breakthrough pain.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018